Fiche publication
Date publication
février 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
Tous les auteurs :
de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Cure H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peigneux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan AT, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl S
Lien Pubmed
Résumé
Background: EGFR is frequently overexpressed in cervical cancer (CC), suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radio-chemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis. Methods: This randomized phaseII trial enrolled 78 FIGO-stage IB2-IIIB CC patients to either Cisplatin based radio-chemotherapy alone (Arm B, n=38) or conjointly with a 6 week course of weekly Cetuximab (Arm A, n=40). Brachytherapy was given to the pelvic mass. Primary endpoint was disease free survival (DFS) at 2 years. EGFR expression and targeted sequencing were performed in 54/78 patients. Findings: Cetuximab over a 6 week period didn't improve DFS at 24 months. At 31 months median follow-up, DFS was not significantly different (p=0*18). Complete response at 4-6 months was strongly predictive for excellent DFS (Log-Rank test; p
Référence
Clin Cancer Res. 2015 Feb 27. pii: clincanres.2368.2014.
